Drug Trial Radar · NCT05803772
A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation in Subjects With a Pathological Oral Glucose Tolerance Test
Last checked: Nov 19, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Mar 31, 2023
Primary completion
Feb 12, 2024
Study completion Feb 12, 2024
Sponsor
- Lead sponsor
- Aphaia Pharma US LLCIndustry
- Sponsor type
- Industry
- First posted
- Apr 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose \[Aphaia technology, AT\]) in participants with pre-diabetes (pathological Oral Glucose Tolerance Test (OGTT)).
Conditions
- PreDiabetes
- Glucose Tolerance Impaired
Interventions
APHD-012Drug
Drug: APHD-012 Distal jejunal-release dextrose beads (Aphaia technology, AT)
APH-012PDrug
Distal jejunal-release placebo beads
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in AUC0-2h values of Oral Glucose Tolerance Test (OGTT) as measured in blood samplesTime frame: Day 1 to Day 42; Day 71 to Day 112
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
ALIAN, s.r.o.
Bardejov, Slovakia
MEDISPEKTRUM s.r.o.
Bratislava, Slovakia
Cell-B s.r.o.
Levice, Slovenska, Slovakia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.